Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

126
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
126
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

100
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
100
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

48
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
48
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

567
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
567
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

53
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
53

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac Remodeling and Dysfunction Associated in Populations With Obesity: An Analysis of Cardiac Structure and Function.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2026
Same author

Addressing the Needs of Patients With Peripheral Artery Disease Through Cardiac Rehabilitation: A Survey of Australian Cardiac Rehabilitation Programs.

Heart, lung & circulation·2026
Same author

Quality Improvement and Quality Indicator-Related Interventions in Cardiac Rehabilitation: A Systematic Review of Economic Evidence Studies.

Heart, lung & circulation·2026
Same author

Serial Changes in Epicardial Adipose Tissue Attenuation Identify Residual Atherosclerotic Risk Independent of LDL Lowering: A Post Hoc Analysis of the CAUGHT-CAD Trial.

JACC. Cardiovascular imaging·2026
Same author

A novel deep learning-based grading system for assessing breast arterial calcification on mammograms, as an independent risk factor for predicting adverse cardiovascular events.

La Radiologia medica·2026
Same author

Regional fat distribution as a determinant of mortality in populations with left ventricular systolic dysfunction: challenging the obesity paradox.

European journal of preventive cardiology·2026

Related Experiment Video

Updated: Oct 13, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.7K

Heart Failure with Reduced Ejection Fraction-Does Sex Matter?

Sascha Swaraj1, Rebecca Kozor1,2, Clare Arnott3

  • 1The Kolling Institute, University of Sydney, Sydney, NSW, Australia.

Current Heart Failure Reports
|November 15, 2021
PubMed
Summary

Sex differences significantly impact heart failure with reduced ejection fraction (HFrEF). Women with HFrEF are older, have more comorbidities, and experience a greater quality of life reduction, highlighting the need for sex-specific research and guidelines.

Keywords:
FemaleGenderHeart failureMaleReduced ejection fractionSex

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.7K

Related Experiment Videos

Last Updated: Oct 13, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.7K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.7K

Area of Science:

  • Cardiology
  • Sex-based Medicine
  • Clinical Research

Background:

  • Sex is increasingly recognized as a critical factor in heart failure susceptibility, presentation, and outcomes.
  • Heart failure with reduced ejection fraction (HFrEF) exhibits distinct biological and clinical characteristics between sexes.

Purpose of the Study:

  • To review current evidence on sex differences in heart failure with reduced ejection fraction (HFrEF).
  • To highlight disparities in biology, clinical features, and treatment strategies relevant to women.
  • To identify areas of unmet need in HFrEF research and clinical practice for females.

Main Methods:

  • Comprehensive literature review focusing on recent findings (last 5 years) related to sex differences in HFrEF.
  • Analysis of clinical trial data regarding female representation and outcomes.
  • Synthesis of evidence on pathophysiology, presentation, morbidity, and mortality in HFrEF.

Main Results:

  • Women with HFrEF are typically older, present with more comorbidities (hypertension, diabetes, obesity), and less often have ischemic heart disease compared to men.
  • Non-ischemic causes are more prevalent in women, who also tend to be more symptomatic.
  • While HFrEF mortality is lower in women, it disproportionately impacts their quality of life.

Conclusions:

  • Distinct sex differences exist in HFrEF pathophysiology, presentation, and outcomes.
  • Increased representation of women in clinical trials is crucial for developing sex-specific management guidelines.
  • Further research is needed to understand the biochemical basis of sex discrepancies in HFrEF.